Prothena Corp (NASDAQ:PRTA) Bolsa

Prothena Corp

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

<h3>Gainers</h3>
<ul>
<li><strong>China SXT Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 45.0% to $1.74 during Friday's after-market session. The company's market cap stands at $23.9 million. </li>
<li><strong>Biodesix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares moved upwards by 16.2% to $0.35. The company's market cap stands at $50.8 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li><strong>Enveric Biosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock increased by 15.88% to $1.53. The market value of their outstanding shares is at $3.7 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li><strong>SS Innovations</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock moved upwards by 9.24% to $10.75. The market value of their outstanding shares is at $2.0 billion. As per the press release, Q1 earnings came out 2 days ago. </li>
<li><strong>Healthcare Triangle</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 8.86% to $0.01. </li>
<li><strong>NanoVibronix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares rose 8.13% to $1.33. The company's market cap stands at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Durect</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares fell 11.4% to $0.57 during Friday's after-market session. The market value of their outstanding shares is at $17.7 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li><strong>Prothena Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 8.83% to $6.55. The company's market cap stands at $352.3 million. </li>
<li><strong>Ensysce Biosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock decreased by 5.99% to $2.2. The company's market cap stands at $3.6 million. The company's, Q1 earnings came out 3 days ago. </li>
<li><strong>PepGen</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) shares fell 5.85% to $1.45. The company's market cap stands at $47.4 million. </li>
<li><strong>Tivic Health Systems</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock fell 5.16% to $4.05. The company's market cap stands at $2.4 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>RAPT Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares fell 5.0% to $0.8. The company's market cap stands at $105.3 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

BDSX

DRRX

ENSC

ENVB

HCTI

NAOV

PEPG

RAPT

SSII

SXTC

TIVC

12 Health Care Stocks Moving In Friday's After-Market Session

<p><a href="https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease">https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease</a>.</p>


Biotech

News

General

ACIU

ANVS

BIIB

DNLI

RHHBF

RHHBY

SAVA

'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and lowers the price target from $48 to $30.</p>


Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Prothena Corp, Lowers Price Target to $30

<p>JMP Securities  analyst Jason Butler   maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Market Outperform and lowers the price target from $80 to $78.</p>


JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $78

<p>In the last three months, 7 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $55.14, along with a high estimate of $110.00 and a low estimate of $20.00. Surpassing the previous average price target of $53.43, the current average has increased by 3.2%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746792092_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Prothena Corp among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Prothena Corp. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Prothena Corp's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Prothena Corp's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Prothena Corp analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Prothena Corp: A Closer Look</h2>
<p>Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.</p>
<h3>Prothena Corp: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Prothena Corp's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>571.84%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Prothena Corp's net margin is impressive, surpassing industry averages. With a net margin of <strong>-2729.91%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Prothena Corp's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-11.35%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Prothena Corp's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-10.15%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Prothena Corp's debt-to-equity ratio is below the industry average. With a ratio of <b>0.02</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 7 Analysts Discuss Prothena Corp Stock

<p>The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.</p>
<p>Here's the latest list of major oversold players in this sector, having an RSI near or below 30.</p>
<h3 class="wp-block-heading"><strong>Prothena Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>)</strong></h3>
<ul class="wp-block-list">
<li>On May 8, Prothena posted weaker-than-expected quarterly results. &#8220;We continue to meaningfully advance our wholly-owned and partnered programs across our protein dysregulation portfolio during this transformative year for Prothena. Most notably in 2025 we anticipate topline data in 2Q from the confirmatory Phase 3 AFFIRM-AL clinical trial evaluating birtamimab for AL amyloidosis, conducted under a SPA agreement with the FDA with a primary endpoint of time to all-cause mortality at a statistical significance level of 0.10,&#8221; said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. The company's stock fell around 31% over the past month and has a 52-week low of $7.01.</li>
<li><strong>RSI Value:</strong> 21.9</li>
<li><strong>PRTA Price Action:</strong> Shares of Prothena fell 2.6% to close at $7.10 on Thursday.</li>
<li>Edge Stock Ratings: 5.29 Momentum score with Value at 79.24. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/PRTA"><img loading="lazy" decoding="async" width="486" height="168" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96.png" alt="" class="wp-image-909704" style="width:347px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96.png 486w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96-300x104.png 300w" sizes="(max-width: 486px) 100vw, 486px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Rxsight Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></h3>
<ul class="wp-block-list">
<li>On May 7, RxSight posted mixed quarterly results. &#8220;The exceptional clinical value delivered by our Light Adjustable Lens continues to drive significant enthusiasm among cataract surgeons,&#8221; said Ron Kurtz, Chief Executive Officer and President of RxSight. The company's stock fell around 15% over the past month and <a href="https://www.benzinga.com/quote/RXST">has a 52-week low</a> of $13.22.</li>
<li><strong>RSI Value:</strong> 28.8</li>
<li><strong>RXST Price Action:</strong> Shares of Rxsight dipped 11.2% to close at $13.23 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">RXST stock</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="917" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97.png" alt="" class="wp-image-909712" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97-768x693.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)</strong></h3>
<ul class="wp-block-list">
<li>On May 6, Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. "In the first quarter, we achieved net product revenue of $611.5 million, a 70% increase over the same quarter prior year; our PMO franchise performed well at $236.5 million; and ELEVIDYS achieved $375 million, growing at 180% over the same quarter prior year. However, we also faced headwinds in the quarter. While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion," said Doug Ingram, CEO of Sarepta Therapeutics. The company's stock fell around 42% over the past five days and has a 52-week l<a href="https://www.benzinga.com/quote/SRPT">ow of $35.4</a>6.</li>
<li><strong>RSI Value:</strong> 23.2</li>
<li><strong>SRPT Price Action:</strong> Shares of Sarepta Therapeutics fell 0.5% to close at $36.52 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">SRPT shares</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="876" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98.png" alt="" class="wp-image-909714" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98.png 876w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98-768x730.png 768w" sizes="(max-width: 876px) 100vw, 876px" /></a></figure></p>
<p>Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> </p>
<p><strong>Read This Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a></strong> </li>
</ul>
<p>Photo via Shutterstock</p>


Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

RXST

SRPT

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

<p>Chardan Capital  analyst Rudy Li   maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $40 price target.</p>


Chardan Capital Maintains Buy on Prothena Corp, Maintains $40 Price Target

<p>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.97) by 15.46 percent. This is a 16.42 percent increase over losses of $(1.34) per share from the same period last year.  The company reported quarterly sales of $2.83 million which missed the analyst consensus estimate of $8.05 million by 64.87 percent.  This is a 5.56K percent increase over sales of $50.00 thousand the same period last year.</p>


Earnings

Earnings Misses

Prothena Corp Q1 EPS $(1.12) Misses $(0.97) Estimate, Sales $2.83M Miss $8.05M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

<p>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Prothena Corp to report an <strong>earnings per share</strong> (EPS) of $-1.03.</p>
<p>The announcement from Prothena Corp is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.04, which was followed by a 2.03% increase in the share price the next day.</p>
<p>Here's a look at Prothena Corp's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.04</td>
<td>-1.18</td>
<td>-1.05</td>
<td>-1.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.08</td>
<td>-1.10</td>
<td>1.22</td>
<td>-1.34</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651746_0.png" alt="eps graph" /></p>
<h3>Market Performance of Prothena Corp's Stock</h3>
<p>Shares of Prothena Corp were trading at $7.35 as of May 06. Over the last 52-week period, shares are down 66.86%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Prothena Corp</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Prothena Corp.</p>
<p>Analysts have provided Prothena Corp with 7 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $58.29, suggesting a potential 693.06% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Regenxbio, Sage Therapeutics and MeiraGTx Hldgs, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Regenxbio, with an average 1-year price target of $32.0, suggesting a potential 335.37% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sage Therapeutics, with an average 1-year price target of $9.5, suggesting a potential 29.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for MeiraGTx Hldgs, with an average 1-year price target of $24.5, suggesting a potential 233.33% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>Within the peer analysis summary, vital metrics for Regenxbio, Sage Therapeutics and MeiraGTx Hldgs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Precigen</td>
<td>Buy</td>
<td>-3.09%</td>
<td>$21K</td>
<td>-42.02%</td>
</tr>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-4.50%</td>
<td>$14.90M</td>
<td>-18.25%</td>
</tr>
<tr>
<td>Sage Therapeutics</td>
<td>Neutral</td>
<td>77.97%</td>
<td>$13.41M</td>
<td>-14.22%</td>
</tr>
<tr>
<td>MeiraGTx Hldgs</td>
<td>Buy</td>
<td>948.53%</td>
<td>$9.58M</td>
<td>-48.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Prothena Corp ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Prothena Corp is at the bottom compared to its peers.</p>
<h3>Unveiling the Story Behind Prothena Corp</h3>
<p>Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.</p>
<h3>Prothena Corp's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Prothena Corp displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>571.84%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Prothena Corp's net margin is impressive, surpassing industry averages. With a net margin of <strong>-2729.91%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Prothena Corp's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-11.35%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-10.15%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Prothena Corp's debt-to-equity ratio is below the industry average at <strong>0.02</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/PRTA/earnings"><strong>To track all earnings releases for Prothena Corp visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Prothena Corp's Earnings Forecast

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>UBS cut <strong>Henry Schein, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $83 to $80. UBS analyst Kevin Caliendo maintained a Neutral rating. Henry Schein shares closed at $75.82 on Tuesday. See how other <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for <strong>Prothena Corporation plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $94 to $110. Piper Sandler analyst Yasmeen Rahimi maintained an Overweight rating. Prothena shares closed at $14.63 on Tuesday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity increased <strong>ZoomInfo Technologies Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) price target from $14 to $15. Canaccord Genuity analyst David Hynes maintained a Buy rating. ZoomInfo shares closed at $9.53 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs cut the price target for <strong>ZipRecruiter, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) from $9 to $8. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating. ZipRecruiter shares closed at $6.73 on Tuesday. <a href="https://www.benzinga.com/quote/ZIP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital raised the price target for <strong>agilon health, inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) from $3 to $3.5. RBC Capital analyst Sean Dodge maintained an Outperform rating. agilon health shares closed at $3.63 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/AGL/analyst-ratings">view this stock</a>.</li>
<li>Roth MKM cut <strong>Shoals Technologies Group, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) price target from $5 to $4.5. Roth MKM analyst Philip Shen maintained a Neutral rating. Shoals Technologies Sports shares settled at $4.2650 on Tuesday. <a href="https://www.benzinga.com/quote/SHLS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer slashed Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) price target from $65 to $60. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Maplebear Brands shares closed at $48.78 on Tuesday. <a href="https://www.benzinga.com/quote/CART/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) price target from $220 to $230. Mizuho analyst Gregg Moskowitz maintained a Neutral rating. Check Point Software shares closed at $218.63 on Tuesday.  <a href="https://www.benzinga.com/quote/CHKP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased the price target for <strong>Jazz Pharmaceuticals pl</strong>c (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from $200 to $209. JP Morgan analyst Jessica Fye maintained an Overweight rating. Jazz Pharmaceuticals shares settled at $139.67 on Tuesday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS increased <strong>CrowdStrike Holdings, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) price target from $396 to $450. UBS analyst Roger Boyd maintained a Buy rating. CrowdStrike shares closed at $379.75 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43981181/nvidia-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Nvidia Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></strong></li>
</ul>


CART

CHKP

CRWD

HSIC

JAZZ

SHLS

CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday

<p>Piper Sandler  analyst Yasmeen Rahimi   maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Overweight and raises the price target from $94 to $110.</p>


Piper Sandler Maintains Overweight on Prothena Corp, Raises Price Target to $110

<p>Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) in the last three months.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $45.33, a high estimate of $80.00, and a low estimate of $20.00. This current average has decreased by 11.12% from the previous average price target of $51.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740402011_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Prothena Corp's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Prothena Corp's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Prothena Corp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Prothena Corp analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Prothena Corp: A Closer Look</h2>
<p>Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).</p>
<h3>Financial Milestones: Prothena Corp's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Prothena Corp's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>118.87%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-2729.91%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-11.35%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Prothena Corp's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-10.15%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.02</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $48 price target.</p>


Reiteration

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $48 Price Target

<p>RBC Capital  analyst Brian Abrahams   maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Sector Perform and lowers the price target from $24 to $20.</p>


RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $20

<p>Cantor Fitzgerald  analyst Eric Schmidt   reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from Overweight to Overweight.</p>


Cantor Fitzgerald Reiterates Overweight on Prothena Corpto Overweight

<p>Citizens Capital Markets  analyst Jason Butler   reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Market Outperform and maintains $80 price target.</p>


Citizens Capital Markets Reiterates Market Outperform on Prothena Corp, Maintains $80 Price Target

<p>The Company expects full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million (midpoint) in cash, cash equivalents and restricted cash.&nbsp;</p>
<p>The estimated full year 2025 net cash used in operating and investing activities is primarily driven by an estimated net loss of $197 to $205 million, which includes an estimated $41 million of non-cash share-based compensation expense.</p>


Guidance

Prothena Estimates FY25 Net Loss Of $(197)M - $(205)M

Press Releases

Prothena Announces Leadership Team Updates

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Announces Board of Directors Update

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Comments

Prothena Corp

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL